論文 Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B J Gastroenterol 2020(Jul.) Author:Matsumoto A, Nishiguchi S, Enomoto H, Tanaka Y, Shinkai N, Okuse C, Kang JH, Matsui T, Miyase S, Yatsuhashi H, Nagaoka S, Kanda T, Enomoto M, Yamada R, Hiramatsu N, Saito S, Takaguchi K, Ito K, Masaki T, Morihara D, Tsuge M, Chayama K, Ikeda F, Kagawa T, Kondo Y, Murata K, Tanaka E
Long-term luseogliflozin therapy improves histological activity of non-alcoholic steatohepatitis accompanied by type 2 diabetes mellitus Clin J Gastroenterol,13(1):83-89 2020(Feb.) Author:Fujimori N, Tanaka N, Kimura T, Sano K, Horiuchi A, Kato N, Takahashi Y, Kuribayashi N, Sugiura A, Yamazaki T, Joshita S, Umemura T, Matsumoto A, Tanaka E
Hepatitis B core-related antigen: a strong indicator for cessation of nucleos(t)ide analog therapy in patients with chronic hepatitis B. J Gastroenterol,52(1):127-128 2017(Jan.) Author:Matsumoto A
A screening method with lymphocyte percentage and proportion of granular lymphocytes in the peripheral blood for large granular lymphocyte (LGL) leukemia. Int J Hematol,105(1):87-91 2017(Jan.) Author:Tanahashi T, Sekiguchi N, Matsuda K, Matsumoto A, Ito T, Nakazawa H, Ishida F
Association between serum soluble CD14 and IL-8 levels and clinical outcome in primary biliary cholangitis. Liver Int,in press 2016(Nov.) Author:Umemura T, Sekiguchi T, Joshita S, Yamazaki T, Fujimori N, Shibata S, Ichikawa Y, Komatsu M, Matsumoto A, Shums Z, Norman GL, Tanaka E, Ota M
Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection. Gut,in press 2016(Oct.) Author:Murata K, Asano M, Matsumoto A, Sugiyama M, Nishida N, Tanaka E, Inoue T, Sakamoto M, Enomoto N, Shirasaki T, Honda M, Kaneko S, Gatanaga H, Oka S, Kawamura YI, Dohi T, Shuno Y, Yano H, Mizokami M
Autoimmune Pancreatitis Can Transform Into Chronic Features Similar to Advanced Chronic Pancreatitis With Functional Insufficiency Following Severe Calcification. Pancreas,45(8):1189-95 2016(Sep.) Author:Kanai K, Maruyama M, Kameko F, Kawasaki K, Asano J, Oguchi T, Watanabe T, Ito T, Muraki T, Hamano H, Matsumoto A, Arakura N, Kawa S
Controlled attenuation parameter is correlated with actual hepatic fat content in patients with non-alcoholic fatty liver disease with none-to-mild obesity and liver fibrosis. Hepatol Res,46(10):1019-27 2016(Sep.) Author:Fujimori N, Tanaka N, Shibata S, Sano K, Yamazaki T, Sekiguchi T, Kitabatake H, Ichikawa Y, Kimura T, Komatsu M, Umemura T, Matsumoto A, Tanaka E
Production of infectious HCV genotype 1b virus in cell culture using a novel Set of adaptive mutations. BMC Microbiol,16(1):224 2016(Sep.) Author:Mori KI, Matsumoto A, Maki N, Ichikawa Y, Tanaka E, Yagi S
Liver stiffness-spleen size-to-platelet ratio risk score identifies esophageal varices in Japanese patients with chronic hepatitis C. Hepatol Res,46(9):884-9 2016(Aug.) Author:Shibata S, Umemura T, Yamazaki T, Fujimori N, Ichikawa Y, Kimura T, Joshita S, Komatsu M, Matsumoto A, Tanaka E
Incidence and prevalence of autoimmune hepatitis in the Ueda area, Japan. Hepatol Res,46(9):878-83 2016(Aug.) Author:Yoshizawa K, Joshita S, Matsumoto A, Umemura T, Tanaka E, Morita S, Maejima T, Ota M
Liver stiffness-spleen size-to-platelet ratio risk score detects esophageal varices in chronic liver disease. Springerplus,5(1):998 2016(Jul.) Author:Shibata S, Joshita S, Umemura T, Yamazaki T, Fujimori N, Ichikawa Y, Komatsu M, Matsumoto A, Tanaka E
Novel and highly sensitive immunoassay for total hepatitis B surface antigen, including that complexed with hepatitis B surface antibody. J Gastroenterol,in press 2016(Jul.) Author:Matsumoto A, Imaizumi M, Tanaka Y, Nishiguchi S, Yatsuhashi H, Ishida T, Moriyama K, Aoyagi K, Tanaka E
Clinicopathological characteristics of non-B non-C hepatocellular carcinoma without past hepatitis B virus infection. Hepatol Res,in press 2016(Jun.) Author:Kimura T, Kobayashi A, Tanaka N, Sano K, Komatsu M, Fujimori N, Yamazaki T, Shibata S, Ichikawa Y, Joshita S, Umemura T, Matsumoto A, Horiuchi A, Mori H, Wada S, Kiyosawa K, Miyagawa SI, Tanaka E
Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein may predict liver fibrosis and progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Hepatol Res,in press 2016(Mar.) Author:Ichikawa Y, Joshita S, Umemura T, Shobugawa Y, Usami Y, Shibata S, Yamazaki T, Fujimori N, Komatsu M, Matsumoto A, Tanaka E
Clinicopathological characterisation of duodenal adenocarcinoma with high CD44 variant 9 expression. Pathology,47(7):647-52 2015(Dec.) Author:Maruyama Y, Uehara T, Daikuhara S, Kobayashi Y, Nakajima T, Matsumoto A, Tanaka E, Ota H
Factors associated with the effect of interferon-α sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B. Hepatol Res,45(12):1195-202 2015(Dec.) Author:Matsumoto A, Yatsuhashi H, Nagaoka S, Suzuki Y, Hosaka T, Tsuge M, Chayama K, Kanda T, Yokosuka O, Nishiguchi S, Saito M, Miyase S, Kang JH, Shinkai N, Tanaka Y, Umemura T, Tanaka E
Association Between Immunoglobulin G4-related Disease and Malignancy within 12 Years after Diagnosis: An Analysis after Longterm Followup. J Rheumatol,42(11):2135-42 2015(Nov.) Author:Asano J, Watanabe T, Oguchi T, Kanai K, Maruyama M, Ito T, Muraki T, Hamano H, Arakura N, Matsumoto A, Kawa S
Serum sodium concentration is associated with increased risk of mortality in patients with compensated liver cirrhosis. Hepatol Res,45(7):739-44 2015(Jul.) Author:Umemura T, Shibata S, Sekiguchi T, Kitabatake H, Nozawa Y, Okuhara S, Kimura T, Morita S, Komatsu M, Matsumoto A, Tanaka E
Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein Level Predicts Liver Fibrosis and Prognosis in Primary Biliary Cirrhosis. Am J Gastroenterol,110(6):857-64 2015(Jun.) Author:Umemura T, Joshita S, Sekiguchi T, Usami Y, Shibata S, Kimura T, Komatsu M, Matsumoto A, Ota M, Tanaka E
Serum cell death biomarkers for prediction of liver fibrosis and poor prognosis in primary biliary cirrhosis. PLoS One,10(6):e0131658 2015(Jun.) Author:Sekiguchi T, Umemura T, Fujimori N, Shibata S, Ichikawa Y, Kimura T, Joshita S, Komatsu M, Matsumoto A, Tanaka E, Ota M
Steatogenesis in adult-onset type II citrullinemia is associated with down-regulation of PPARα. Biochim Biophys Acta,1852(3):473-81 2015(Mar.) Author:Komatsu M, Kimura T, Yazaki M, Tanaka N, Yang Y, Nakajima T, Horiuchi A, Fang ZZ, Joshita S, Matsumoto A, Umemura T, Tanaka E, Gonzalez FJ, Ikeda S, Aoyama T
Mutations of pre-core and basal core promoter before and after hepatitis B e antigen seroconversion. World J Gastroenterol,21(2):541-8 2015(Jan.) Author:Kamijo N, Matsumoto A, Umemura T, Shibata S, Ichikawa Y, Kimura T, Komatsu M, Tanaka E
Human Leukocyte Antigen Class II Haplotypes Affect Clinical Characteristics and Progression of Type 1 Autoimmune Hepatitis in Japan PLOS ONE,9(6):e100565 2014(Jun.) Author:Umemura, T; Katsuyama, Y; Yoshizawa, K; Kimura, T; Joshita, S; Komatsu, M; Matsumoto, A; Tanaka, E; Ota, M
Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B HEPATOLOGY RESEARCH,44(1):1-8 2014(Jan.) Author:Tanaka, E; Matsumoto, A
STAT4 Gene Polymorphisms Are Associated with Susceptibility and ANA Status in Primary Biliary Cirrhosis DISEASE MARKERS,2014:727393 2014 Author:Joshita, S; Umemura, T; Nakamura, M; Katsuyama, Y; Shibata, S; Kimura, T; Morita, S; Komatsu, M; Matsumoto, A; Yoshizawa, K; Ishibashi, H; Tanaka, E; Ota, M
Comparison of carbon dioxide and air insufflation use by non-expert endoscopists during endoscopic retrograde cholangiopancreatography DIGESTIVE ENDOSCOPY,25(2):189-196 2013(Mar.) Author:Muraki, T; Arakura, N; Kodama, R; Yoneda, S; Maruyama, M; Itou, T; Watanabe, T; Maruyama, M; Matsumoto, A; Kawa, S; Tanaka, E
Association analysis of toll-like receptor 4 polymorphisms in Japanese primary biliary cirrhosis Hum Immunol,74(2):219-222 2013(Feb.) Author:Morita, S; Joshita, S; Umemura, T; Katsuyama, Y; Kimura, T; Komatsu, M; Matsumoto, A; Yoshizawa, K; Kamijo, A; Yamamura, N; Tanaka, E; Ota, M
Type 1 autoimmune pancreatitis can transform into chronic pancreatitis: a long-term follow-up study of 73 Japanese patients International Journal of Rheumatology,2013:272595 2013 Author:Maruyama M, Arakura N, Ozaki Y, Watanabe T, Ito T, Yoneda S, Maruyama M, Muraki T, Hamano H, Matsumoto A, Kawa S.
Changes in the serum level of hepatitis B virus (HBV) surface antigen over the natural course of HBV infection J Gastroenterol,47(9):1006-13 2012(Sep.) Author:Matsumoto A, Tanaka E, Morita S, Yoshizawa K, Umemura T, Joshita S
Long-term outcome of japanese patients with type 1 autoimmune hepatitis Hepatology,56(2):668-76 2012(Aug.) Author:Yoshizawa K, Matsumoto A, Ichijo T, Umemura T, Joshita S, Komatsu M, Tanaka N, Tanaka E, Ota M, Katsuyama Y, Kiyosawa K, Abe M, Onji M
Clinical characteristics of young-onset ischemic colitis Dig Dis Sci,57(6):1652-9 2012(Jun.) Author:Kimura T, Shinji A, Horiuchi A, Tanaka N, Nagaya T, Shigeno T, Nakamura N, Komatsu M, Umemura T, Arakura N, Matsumoto A, Tanaka E
Risk factors for pancreatic stone formation in autoimmune pancreatitis over a long-term course J Gastroenterol,47(5):553-60 2012(May) Author:Maruyama M, Arakura N, Ozaki Y, Watanabe T, Ito T, Yoneda S, Muraki T, Hamano H, Matsumoto A, Kawa S
Association of IL28B gene polymorphism with development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C virus infection Hum Immunol,73(3):298-300 2012(Mar.) Author:Joshita S, Umemura T, Katsuyama Y, Ichikawa Y, Kimura T, Morita S, Kamijo A, Komatsu M, Ichijo T, Matsumoto A, Yoshizawa K, Kamijo N, Ota M, Tanaka E
Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B Hepatol Res,42(2):139-149 2012(Feb.) Author:Matsumoto A, Tanaka E, Suzuki Y, Kobayashi M, Tanaka Y, Shinkai N, Hige S, Yatsuhashi H, Nagaoka S, Chayama K, Tsuge M, Yokosuka O, Imazeki F, Nishiguchi S, Saito M, Fujiwara K, Torii N, Hiramatsu N, Karino Y, Kumada H
Early detection of interstitial pneumonia by monitoring KL-6 in a chronic hepatitis C patient undergoing pegylated interferon and ribavirin therapy Hepatol Res,41(9):904-9 2011(Sep.) Author:Ichikawa-Yamada Y, Joshita S, Tsukahara Y, Kimura T, Morita S, Kamijo A, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Tanaka E
Serum chemokine levels are associated with the outcome of pegylated interferon and ribavirin therapy in patients with chronic hepatitis C Hepatol Res,41(6):587-93 2011(Jun.) Author:Yoneda S, Umemura T, Joshita S, Ichijo T, Matsumoto A, Yoshizawa K, Katsuyama Y, Ota M, Tanaka E
Kidney transplantation recovers the reduction level of serum sulfatide in ESRD patients via processes correlated to oxidative stress and platelet count Glycoconj J,28(3-4):125-35 2011(May) Author:Wang L, Kamijo Y, Matsumoto A, Nakajima T, Higuchi M, Kannagi R, Kyogashima M, Aoyama T, Hara A
Cytokine profiles affecting the pathogenesis of autoimmune hepatitis in Japanese patients Hepatol Res,41(4):350-7 2011(Apr.) Author:Kamijo A, Yoshizawa K, Joshita S, Yoneda S, Umemura T, Ichijo T, Matsumoto A, Ota M, Tanaka E
Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C J Gastroenterol,46(4):545-55 2011(Apr.) Author:Chayama K, Hayes CN, Yoshioka K, Moriwaki H, Okanoue T, Sakisaka S, Takehara T, Oketani M, Toyota J, Izumi N, Hiasa Y, Matsumoto A, Nomura H, Seike M, Ueno Y, Yotsuyanagi H, Kumada H
Association of Serum Cytokine Levels with Treatment Response to Pegylated Interferon and Ribavirin Therapy in Genotype 1 Chronic Hepatitis C Patients J Infect Dis,203(8):1087-95 2011(Mar.) Author:Yoneda S, Umemura T, Katsuyama Y, Kamijo A, Joshita S, Komatsu M, Ichijo T, Matsumoto A, Yoshizawa K, Ota M, Tanaka E
Serum interleukin (IL)-10 and IL-12 levels and IL28B gene polymorphisms: pretreatment prediction of treatment failure in chronic hepatitis C Antivir Ther,16(7):1073-80 2011 Author:Umemura T, Joshita S, Yoneda S, Katsuyama Y, Ichijo T, Matsumoto A, Yoshizawa K, Ota M, Tanaka E
A Case of Pyogenic Liver Abscess Infected with Fusobacterium necrophorum Depicted by Microscopy and Confirmed by Tissue Culture Intern Med,50(17):1815-9 2011 Author:Nozawa Y, Joshita S, Fukushima M, Sugiyama Y, Ichikawa Y, Kimura T, Morita S, Kamijo A, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Tanaka E
Down-regulation of SREBP-1c is associated with the development of burned-out NASH J Hepatol,53(4):724-31 2010(Oct.) Author:Nagaya T, Tanaka N, Suzuki T, Sano K, Horiuchi A, Komatsu M, Nakajima T, Nishizawa T, Joshita S, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Nakayama J, Tanaka E, Aoyama T
Comparison of hepatitis B virus DNA, RNA, and core related antigen as predictors of lamivudine resistance in patients with chronic hepatitis B Shinshu Med J,58(4):153-162 2010(Aug.) Author:Matsumoto A, Maki N, Yoshizawa K, Umemura T, Joshita S, Tanaka E
Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels J Clin Gastroenterol,44(6):440-7 2010(Jul.) Author:Tsutsui M, Tanaka N, Kawakubo M, Sheena Y, Horiuchi A, Komatsu M, Nagaya T, Joshita S, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Aoyama T, Tanaka E, Sano K
Nonalcoholic fatty liver disease in Japanese junior high school students: its prevalence and relationship to lifestyle habits J Gastroenterol,45(6):666-72 2010(Jun.) Author:Tsuruta G, Tanaka N, Hongo M, Komatsu M, Horiuchi A, Hamamoto K, Iguchi C, Nakayama Y, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Aoyama T, Tanaka E
A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome Intern Med,49(11):991-4 2010(Jun.) Author:Joshita S, Yoshizawa K, Sano K, Kobayashi S, Sekiguchi T, Morita S, Kamijo A, Komatsu M, Umemura T, Ichijo T, Matsumoto A, Tanaka E
Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in patients with chronic hepatitis C, using viral and host factors: some concerns (reply) Hepatology,49(6):2125 2009(Jun.) Author:Matsumoto A, Tanaka E
Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors Hepatology,48(6):1753-60 2008(Dec.) Author:Shirakawa H, Matsumoto A, Joshita S, Komatsu M, Tanaka N, Umemura T, Ichijo T, Yoshizawa K, Kiyosawa K, Tanaka E
Insulin resistance and hepatitis C virus: a case-control study of non-obese, non-alcoholic and non-steatotic hepatitis virus carriers with persistently normal serum aminotransferase Liver Int,28(8):1104-11 2008(Sep.) Author:Tanaka N, Nagaya T, Komatsu M, Horiuchi A, Tsuruta G, Shirakawa H, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Aoyama T, Kiyosawa K, Tanaka E
Hepatitis B core-related antigen assay is useful for monitoring the antiviral effects of nucleoside analogue therapy Intervirology,51 Suppl 1:3-6 2008 Author:Tanaka E, Matsumoto A, Yoshizawa K, Maki N
Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy Hepatol Res,37(8):661-6 2007(Aug.) Author:Matsumoto A, Tanaka E, Minami M, Okanoue T, Yatsuhashi H, Nagaoka S, Suzuki F, Kobayashi M, Chayama K, Imamura M, Yotsuyanagi H, Nakaoka S, Maki N, Kawata S, Kumada H, Iino S, Kiyosawa K
Anti-Helicobacter pylori seropositivity: influence on severity and treatment response in patients with chronic hepatitis C J Viral Hepat,14(1):48-54 2007(Jan.) Author:Umemura T, Muto H, Tanaka E, Matsumoto A, Ichijo T, Yoshizawa K, Akamatsu T, Kiyosawa K